NPPA directs pharma firms to provide PTR, MAT details for 29 formulations
New Delhi: In order to take appropriate action for ceiling price fixation under the provisions of the DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA) has asked concerned manufacturers and marketing companies of 29 formulations to furnish information regarding Price To Retailer (PTR) and Moving Annual Turnover (MAT) in value term for the month of March 2021.In this regard,...
New Delhi: In order to take appropriate action for ceiling price fixation under the provisions of the DPCO, 2013, the National Pharmaceutical Pricing Authority (NPPA) has asked concerned manufacturers and marketing companies of 29 formulations to furnish information regarding Price To Retailer (PTR) and Moving Annual Turnover (MAT) in value term for the month of March 2021.
In this regard, the Authority has issued an Office Memorandum (OM) requesting the concerned manufacturers / marketing firms provide information on Price To Retailer (PTR) and Moving Annual Turnover (MAT) for the formulations listed in Annexure-A, in the manner specified in Annexure-B.
SI. No. | Formulation | Dosage form and Strength |
1 | Abacavir | Tablet60 mg |
2 | Acetylsalicylic acid | Effervescent/ Dispersible/ Enteric coated Tablet 300 mgto 500 mg |
3 | Acetylsalicylic acid | Tablet 300 mg to 500 mg (351mg to 500mg) |
4 | Activated charcoal | Powder (as licensed) |
5 | Calcium carbonate | Tablet 250 mg |
6 | Calcium folinate | Injection 3 mg/ml |
7 | Cloxacillin | Oral Liquid 125 mg/5 ml |
8 | Cycloserine | Capsule 125 mg |
9 | Dapsone | Tablet 50 mg |
10 | Dry syrup 50 mg/5 ml | |
11 | Ethionamide | Tablet 125 mg |
12 | Ferrous salt (A)+ Folic acid (BJ | Oral liqiud 20 mg elemental iron (A)+ 100 mcg |
13 | Ferrous salts | Tablet equivalent to 60 mg of elemental iron |
14 | Hydroxocobalamin | Injection 1 mg/ml |
15 | lohexol | Injection 140 to 350 mg iodine/ml |
16 | Lamivudine (A) + Zidovudine (BJ | Tablet 30 mg (A) + 60 mg (BJ |
17 | Medroxyprogesteroneacetate | Tablet 5 mg |
18 | Methylthioninium chloride (Methylene blue) | Injection 10 mg/ml |
19 | Miltefosine | Capsule 50 mg |
20 | Nevirapine | Dispersible Tablet 50 mg |
21 | Nystatin | Pessary 100,000 IU |
22 | Nystatin | Oral Liquid 100, 000 IU/ml |
23 | Paromomycin | Injection 375 mg/ml |
24 | Povidone iodine | Drops 5% |
25 | Pyridoxine | Tablet 50 mg |
26 | Sodium chloride | Injection 3% |
27 | Vitamin A | Oral liquid 100000 JU/ml |
28 | Zidovudine | Oral liquid 50 mg/5 ml |
29 | Zidovudine (A)+ Lamivudine (B) + Nevirapine (C) | Tablet 60 mg (A) + 30 mg (B) + 50 mg (C) |
Annexure-B
Name of the Company: _______________________________________________________
SI. No. | Medicine | Dosage form and Strength | Brand | Pack size | Moving Annual Turnover (MAT) as on March 2021 | Price To Retailer(PTR) as on March 2021 |
To view the official OM, click the link below:
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd